Final Program

MONDAY • MAY 16 189
P87
P88
P89
P90
P91
P92
P93
P94
Facilitator:
P95
P96
P97
P98
P99
P100
Cytokine Levels as Predictors of Pulmonary Arterial
Hypertension in Human Immunodeficiency Virus Seropositive
Subjects/M. Henriques-Forsythe, T. Tewolde, M.B. Huang, H.W.
Farber, A. Quarshie, V.C. Bond, Atlanta, GA, p.A3954
Higher Prevalence of Pulmonary Hypertension Among an
African American HIV-Infected Cohort/M. Henriques-Forsythe, T.
Tewolde, R. Lapu-Bula, H.W. Farber, A. Onwuanyi, Atlanta, GA,
p.A3955
Efficacy and Safety of Inhaled Sodium Nitrite in Pulmonary
Hypertension Associated with Heart Failure with Preserved
Ejection Fraction/M.A. Simon, R.R. Vanderpool, T.N. Bachman, P.
White, E.L. Parsley, M.T. Gladwin, Pittsburgh, PA, p.A3956
Neutrophil- to-Lymphocyte Ratio Predicts Survival in
Pulmonary Arterial Hypertension Patients/V. Foris, G. Kovacs,
P. Douschan, A. Avian, A. Olschewski, H. Olschewski, Graz,
Austria, p.A3957
Characteristics of Precapillary Pulmonary Hypertension in
Elderly and Very Elderly Patients/M. Ginoux, S. Turquier, J.C.
Glerant, J. Traclet, C. Khouatra, F. Philit, A. Senechal, J.-F.
Mornex, V. Cottin, Bron, France, p.A3958
Is Right Heart Catheterization Justified in Very Elderly
Patients?/M. Ginoux, V. Cottin, J.C. Glerant, J. Traclet, C.
Khouatra, F. Philit, A. Senechal, J.-F. Mornex, S. Turquier, Bron,
France, p.A3959
Circulating RNA as Potential Biomarkers in Pulmonary
Hypertension/I. Singh, K. Max, D. Berger, K. Bogardus, T. Tuschl,
E. Horn, K. Akat, New York, NY, p.A3960
Using Near-Infrared Spectroscopy to Characterize the Effects
of Inhaled Nitric Oxide on Skeletal Muscle Oxygen Saturation
in Adults with Pulmonary Arterial Hypertension/B.D. Shaller, C.
Kholdani, H. Hedlin, A.J. Sweatt, A. Hsi, E.F. Spiekerkoetter, R.T.
Zamanian, Stanford, CA, p.A3961
N. Al-Naamani, MD, Boston, MA
The Spatial Distribution of Pulmonary Blood Flow in Adults
Who Have Undergone Fontan Procedure/S.R. Hopkins, B.F.
Printz, R.C. Sa, H.G. El-Said, C.K. Davis, R.J. Theilmann, La Jolla,
CA, p.A3962
Pulmonary Arterial Hypertension: Effect of Online CME on
Improving Treatment Decisions/J. Spyropoulos, C.C. Kearns,
R.J. White, New York, NY, p.A3963
Pulmonary Arterial Hypertension (PAH) Associated with
Interferon Therapy: A Population Based Study/R. Papani, A.
Duarte, Y.L. Lin, G. Sharma, Galveston, TX, p.A3964
Portopulmonary Hypertension Following Splenectomy: A Mayo
Clinic Experience/J.M. Segraves, R. Cartin-Ceba, M.J. Krowka,
Rochester, MN, p.A3965
Interstitial Lung Disease Associated Pulmonary Hypertension
in China/L. Wang, Q.-H. Zhao, R. Jiang, S.-G. Gong, J. He, P.
Yuan, J.-M. Liu, Shanghai, China, p.A3966
Pulmonary Function Test Parameters in Patients with
Scleroderma-Associated Pulmonary Arterial Hypertension and
Correlation with Mean Pulmonary Artery Pressure and
Pulmonary Vascular Resistance/V. Yap, A. Selvachandran, M.
Zantah, R. Foley, D. Datta, Farmington, CT, p.A3967
P101
P102
P103
P104
P105
P106
P107
P108
Facilitator:
P109
P110
P111
P112
P113
Does Riociguat Provide Clinical Improvement in Pulmonary
Hypertension? - A Meta Analysis/M. Anantha Narayanan, A.
Kanmanthareddy, H. Devineni, J. Baskaran, L.E. Morrow, T.O.
Wichman, Omaha, NE, p.A3968
Characteristics and Diagnoses of Elderly Patients Referred to
a Pulmonary Vascular Clinic for Evaluation of Possible
Pulmonary Arterial Hypertension/H. Edriss, K. Selvan, T.
Denega, T. Rodrigues, K. Nugent, Lubbock, TX, p.A3969
Safety and Tolerability of Outpatient Transition of Parenteral
and Inhaled Treprostinil to Oral Treprostinil in Patients with
Pulmonary Arterial Hypertension/A.A. Khan, K. Ackerbauer, R.
Tandon, Chicago, IL, p.A3970
A Comparison of Safety and Pharmacokinetics of
Esuberaprost (BPS-314d-MR) in Subjects with Normal, Mild
and Moderate Hepatic Impairment/K.R.B.V. Kessler, T. Marbury,
K. Lasseter, J. Berg, G. Patel, X. Chen, S. Peychal, J. Shin, P.
Sista, Silver Spring, MD, p.A3971
Connective Tissue Disease Associated Pulmonary Arterial
Hypertension (CTD-PAH) - Prognosis, Predictors and
Outcomes (PROPOS) Study/R. Ronaghi, B. Doremus, A.I. Khan,
V. Balasubramanian, Fresno, CA, p.A3972
Diabetes and Group III Pulmonary Hypertension: A Matched
Case-Control Study/V.K. Singh, A.M. Morris, P. George,
Monroeville, PA, p.A3973
Pulmonary Capillary Wedge Pressure (PCWP) and Its Role in
Determining Outcomes in Pulmonary Arterial Hypertension
(PAH)/S. Venepally, R. Ronaghi, A.I. Khan, V. Balasubramanian,
Fresno, CA, p.A3974
Evaluating the Role of a Pulmonary Hypertension Specialist
Nurse in Early Referral/L.E. Loewenthal, E.J. Shaw, B.P.
Brendan, London, United Kingdom, p.A3975
H.J. Ford, MD, Chapel Hill, NC
Clinical Significance of Detecting Pulmonary Arterio-Venous
Malformations with Chest Radiographs/K. Yamamoto, T.
Sugiura, Y. Kasahara, S. Sakao, N. Tanabe, K. Tatsumi, Chiba,
Japan, p.A3976
TRANSIT-1: Evaluation of Transition from Inhaled Treprostinil
to Oral Selexipag/A. Frost, R.L. Benza, H. Farber, N.H. Kim, B.K.
Hartline, T. Pfister, Y. Shiraga, V. McLaughlin, Houston, TX,
p.A3977
Low Rate of Adverse Events Associated with Inpatient
Parenteral Prostacyclins/K. Albujoq, R. Awdish, L. Yessayan, M.
Mendez, J. Jennings, N. MacDonald, H. Cajigas, S. Hegab, Detroit,
MI, p.A3978
Patients with Pulmonary Arterial Hypertension Less
Represented in Clinical Trials - Who Are They and How Are
They?/G. Kovacs, A. Avian, P. Douschan, V. Foris, A. Olschewski,
H. Olschewski, Graz, Austria, p.A3979
Novel PET Vascular Biomarkers in Pulmonary Arterial
Hypertension/V.J. Kelly, P. Kohli, T. Winkler, E. Kehl, J.
Rodriguez-Lopez, K.A. Hibbert, M. Kone, J.G. Venegas, R.N.
Channick, R.S. Harris, Boston, MA, p.A3980
MONDAY MORNING
ATS 2016 • San Francisco